NCT04974684View on ClinicalTrials.gov

DOT HeartMate 3 Study

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
LVAD (Left Ventricular Assist Device) Thrombosis
Interventions
DEVICE

HeartMate 3

Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.

DRUG

Apixaban

Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.

Trial Locations (1)

14021

Institute for Clinical and Experimental Medicine, Prague

All Listed Sponsors
lead

Institute for Clinical and Experimental Medicine

OTHER_GOV